Stearyl norleucine vasointestinal peptide

Drug Profile

Stearyl norleucine vasointestinal peptide

Alternative Names: SNV; Stearyl norleucine VIP

Latest Information Update: 06 Nov 2002

Price : $50

At a glance

  • Originator Nonindustrial sources
  • Developer Senetek
  • Class
  • Mechanism of Action Vasoactive intestinal peptide receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Erectile dysfunction; Female sexual dysfunction

Most Recent Events

  • 05 Nov 2002 No development reported - Preclinical for Erectile dysfunction in USA (Topical)
  • 05 Nov 2002 No development reported - Preclinical for Female sexual dysfunction in USA (Topical)
  • 25 Sep 2000 Preclinical development for Erectile dysfunction in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top